GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · BSE Equity Only

BSE Exchange Filings, Explained Simply

AI-powered plain-English analysis of every important BSE announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Today
—
Total
BSE
Exchange
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Strictly sourced from BSE exchange announcements (equity segment only). We show only material, important filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India exchange announcements. More categories will be added over time.
Indrayani Biotech Ltd
Indrayani Biotech Postpones Rights Issue Schedule Indefinitely
FUNDRAISE ◆ Monitor Closely MEDIUM RISK
📅 Filed on BSE: 22 Jun 2026, 04:09 PM IST  ·  BSE ID: 6c2c1b05-7ddc-4bcd-8833-84fd47ee234a
View Original BSE Filing (PDF)
💡
In Simple Terms
The company decided to delay its upcoming share sale to existing investors until further notice.
🤖 AI Summary
  • Indrayani Biotech indefinitely postpones its partly paid-up Rights Issue.
  • Rights Issue schedule originally set for May 27-June 25, 2026, extended to July 24.
  • New opening and closing dates will be intimated separately once finalized.
  • Offer price and rights entitlement ratio remain unchanged from previous intimations.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Rights Issue Amount
Rs. 49.90 crore
Original Issue Close Date
June 25, 2026
Extended Issue Close Date
July 24, 2026
🏢 How This Affects the Company
📈
Business Impact
The delay in the Rights Issue postpones the expected capital infusion, potentially impacting near-term business expansion plans that relied on this funding.
💰
Financial Impact
The postponement defers the expected Rs. 49.90 crore capital raise, impacting the company's cash flow and balance sheet strengthening objectives.
⚙️
Operational Impact
There is no immediate operational impact, but future expansion or strategic initiatives dependent on the rights issue proceeds are now on hold.
⚠️
Risk Impact
The indefinite postponement introduces uncertainty regarding the timing of capital inflow and may necessitate adjustments to financial planning.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders regarding the Rights Issue schedule postponement.
👤
Who Is Affected
All eligible equity shareholders who were to participate in the partly paid-up Rights Issue are affected by the schedule change.
🔍
Management Signal
The decision signals management's intent to proceed with the Rights Issue but requires further time to finalize its schedule.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Intimation of revised Rights Issue opening and closing dates.
Company website for updated issue documents.
Future board meeting outcomes for Rights Issue updates.
MEDIUM RISK Indefinite postponement of a key capital raising event introduces execution risk.
💡 Investor Takeaway
Indrayani Biotech has postponed its partly paid-up Rights Issue, originally set to close July 24, 2026, until further notice. Offer price and entitlement ratio remain unchanged.
⚖️ Strengths & Concerns

⚠️ Concerns

  • Indefinite postponement of Rs. 49.90 crore partly paid-up Rights Issue creates uncertainty for capital raising.
  • Delay in Rights Issue schedule indicates potential challenges in finalizing terms or market conditions.
📅 Company Track Record
Previous intimations in April 2026 confirmed a Rs. 49.90 crore partly paid rights issue, expanding equity by 71% to 7,80,62,153 shares at Rs. 15 fully paid.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What is the current status of Indrayani Biotech's Rights Issue?
Indrayani Biotech has postponed its partly paid-up Rights Issue indefinitely. The new schedule will be announced later.
What is the total value of the Rights Issue?
The Rights Issue is for Rs. 49.90 crore, as previously approved.
When was the Rights Issue originally scheduled to close?
The Rights Issue was initially scheduled to close on June 25, 2026, and was extended to July 24, 2026, before being postponed.
Have the terms of the Rights Issue changed?
No, the terms relating to the offer price and rights entitlement ratio remain the same as previously approved.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.